These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 28705885)

  • 1. Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease.
    Chonchol M; Gitomer B; Isakova T; Cai X; Salusky I; Pereira R; Abebe K; Torres V; Steinman TI; Grantham JJ; Chapman AB; Schrier RW; Wolf M
    Clin J Am Soc Nephrol; 2017 Sep; 12(9):1461-1469. PubMed ID: 28705885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials.
    Brosnahan GM; Abebe KZ; Rahbari-Oskoui FF; Patterson CG; Bae KT; Schrier RW; Braun WE; Chapman AB; Flessner MF; Harris PC; Perrone RD; Steinman TI; Torres VE;
    Curr Hypertens Rev; 2017; 13(2):109-120. PubMed ID: 28460625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Uric Acid and Progression of Autosomal Dominant Polycystic Kidney Disease: Results from the HALT PKD Trials.
    Brosnahan GM; You Z; Wang W; Gitomer BY; Chonchol M
    Curr Hypertens Rev; 2021; 17(3):228-237. PubMed ID: 32807060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials.
    Brosnahan GM; Abebe KZ; Moore CG; Rahbari-Oskoui FF; Bae KT; Grantham JJ; Schrier RW; Braun WE; Chapman AB; Flessner MF; Harris PC; Hogan MC; Perrone RD; Miskulin DC; Steinman TI; Torres VE;
    Am J Kidney Dis; 2018 May; 71(5):666-676. PubMed ID: 29306517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease.
    Hayek SS; Landsittel DP; Wei C; Zeier M; Yu ASL; Torres VE; Roth S; Pao CS; Reiser J
    J Am Soc Nephrol; 2019 Jul; 30(7):1305-1313. PubMed ID: 31171572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease.
    Torres VE; Abebe KZ; Schrier RW; Perrone RD; Chapman AB; Yu AS; Braun WE; Steinman TI; Brosnahan G; Hogan MC; Rahbari FF; Grantham JJ; Bae KT; Moore CG; Flessner MF
    Kidney Int; 2017 Feb; 91(2):493-500. PubMed ID: 27993381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary Angiotensinogen in addition to Imaging Classification in the Prediction of Renal Outcome in Autosomal Dominant Polycystic Kidney Disease.
    Park HC; Kim J; Cho A; Kim DH; Lee YK; Ryu H; Kim H; Oh KH; Oh YK; Hwang YH; Lee KB; Kim SW; Kim YH; Lee J; Ahn C;
    J Korean Med Sci; 2020 Jun; 35(22):e165. PubMed ID: 32508065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effect of coffee consumption on autosomal dominant polycystic kidneys disease progression: results from the Suisse ADPKD, a Prospective Longitudinal Cohort Study.
    Girardat-Rotar L; Puhan MA; Braun J; Serra AL
    J Nephrol; 2018 Feb; 31(1):87-94. PubMed ID: 28386880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KIM-1 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease: HALT-PKD Results.
    Griffin BR; You Z; Noureddine L; Gitomer B; Perrenoud L; Wang W; Chonchol M; Jalal D;
    Am J Nephrol; 2020; 51(6):473-479. PubMed ID: 32541154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between Monocyte Count and Risk of Incident CKD and Progression to ESRD.
    Bowe B; Xie Y; Xian H; Li T; Al-Aly Z
    Clin J Am Soc Nephrol; 2017 Apr; 12(4):603-613. PubMed ID: 28348030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NT-proBNP and troponin T and risk of rapid kidney function decline and incident CKD in elderly adults.
    Bansal N; Katz R; Dalrymple L; de Boer I; DeFilippi C; Kestenbaum B; Park M; Sarnak M; Seliger S; Shlipak M
    Clin J Am Soc Nephrol; 2015 Feb; 10(2):205-14. PubMed ID: 25605700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.
    Edwards ME; Chebib FT; Irazabal MV; Ofstie TG; Bungum LA; Metzger AJ; Senum SR; Hogan MC; El-Zoghby ZM; Kline TL; Harris PC; Czerwiec FS; Torres VE
    Clin J Am Soc Nephrol; 2018 Aug; 13(8):1153-1161. PubMed ID: 30026287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors predicting decline in renal function and kidney volume growth in autosomal dominant polycystic kidney disease: a prospective cohort study (Japanese Polycystic Kidney Disease registry: J-PKD).
    Uchiyama K; Mochizuki T; Shimada Y; Nishio S; Kataoka H; Mitobe M; Tsuchiya K; Hanaoka K; Ubara Y; Suwabe T; Sekine A; Nutahara K; Tsuruya K; Ishimura E; Nakatani S; Sofue T; Tanaka S; Narita I; Maruyama S; Horie S; Muto S
    Clin Exp Nephrol; 2021 Sep; 25(9):970-980. PubMed ID: 33928479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade?
    Brosnahan GM; Abebe KZ; Moore CG; Bae KT; Braun WE; Chapman AB; Flessner MF; Harris PC; Hogan MC; Perrone RD; Rahbari-Oskoui FF; Steinman TI; Torres VE; The Halt Pkd Investigators
    Curr Hypertens Rev; 2018; 14(1):39-47. PubMed ID: 29564978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble klotho and autosomal dominant polycystic kidney disease.
    Pavik I; Jaeger P; Ebner L; Poster D; Krauer F; Kistler AD; Rentsch K; Andreisek G; Wagner CA; Devuyst O; Wüthrich RP; Schmid C; Serra AL
    Clin J Am Soc Nephrol; 2012 Feb; 7(2):248-57. PubMed ID: 22193235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kidney Function Reserve Capacity in Early and Later Stage Autosomal Dominant Polycystic Kidney Disease.
    Messchendorp AL; van Londen M; Taylor JM; de Borst MH; Navis G; Casteleijn NF; Gaillard CAJM; Bakker SJL; Gansevoort RT;
    Clin J Am Soc Nephrol; 2018 Nov; 13(11):1680-1692. PubMed ID: 30254028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial.
    Irazabal MV; Abebe KZ; Bae KT; Perrone RD; Chapman AB; Schrier RW; Yu AS; Braun WE; Steinman TI; Harris PC; Flessner MF; Torres VE;
    Nephrol Dial Transplant; 2017 Nov; 32(11):1857-1865. PubMed ID: 27484667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
    Torres VE; Higashihara E; Devuyst O; Chapman AB; Gansevoort RT; Grantham JJ; Perrone RD; Ouyang J; Blais JD; Czerwiec FS;
    Clin J Am Soc Nephrol; 2016 May; 11(5):803-811. PubMed ID: 26912543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kidney phosphate wasting predicts poor outcome in polycystic kidney disease.
    Xue L; Geurts F; Meijer E; de Borst MH; Gansevoort RT; Zietse R; Hoorn EJ; Salih M;
    Nephrol Dial Transplant; 2024 Jun; 39(7):1105-1114. PubMed ID: 37985930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations of Proximal Tubular Secretion in Autosomal Dominant Polycystic Kidney Disease.
    Wang K; Zelnick LR; Chen Y; Hoofnagle AN; Watnick T; Seliger S; Kestenbaum B
    Clin J Am Soc Nephrol; 2020 Jan; 15(1):80-88. PubMed ID: 31628117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.